| The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer Y Fujita, S Yagishita, K Hagiwara, Y Yoshioka, N Kosaka, F Takeshita, ... Molecular therapy 23 (4), 717-727, 2015 | 253 | 2015 |
| Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer K Muraki, R Koyama, Y Honma, S Yagishita, T Shukuya, R Ohashi, ... Journal of thoracic disease 4 (6), 562, 2012 | 82 | 2012 |
| Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer H Horinouchi, N Yamamoto, Y Fujiwara, I Sekine, H Nokihara, K Kubota, ... Investigational new drugs 33, 881-889, 2015 | 57 | 2015 |
| Difference in SARS-CoV-2 antibody status between patients with cancer and health care workers during the COVID-19 pandemic in Japan S Yazaki, T Yoshida, Y Kojima, S Yagishita, H Nakahama, K Okinaka, ... JAMA oncology 7 (8), 1141-1148, 2021 | 56 | 2021 |
| A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies K Noda, K Matsuda, S Yagishita, K Maeda, Y Akiyama, ... Scientific reports 11 (1), 5198, 2021 | 56 | 2021 |
| Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells I Kobayashi, F Takahashi, F Nurwidya, T Nara, M Hashimoto, A Murakami, ... Biochemical and biophysical research communications 473 (1), 125-132, 2016 | 55 | 2016 |
| Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non–small-cell lung … S Yagishita, H Horinouchi, TK Taniyama, S Nakamichi, S Kitazono, ... International Journal of Radiation Oncology* Biology* Physics 91 (1), 140-148, 2015 | 53 | 2015 |
| Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial–mesenchymal transition in non-small cell lung cancer F Nurwidya, F Takahashi, I Kobayashi, A Murakami, M Kato, K Minakata, ... Biochemical and biophysical research communications 455 (3-4), 332-338, 2014 | 44 | 2014 |
| Trastuzumab deruxtecan for human epidermal growth factor receptor 2–expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial T Nishikawa, K Hasegawa, K Matsumoto, M Mori, Y Hirashima, ... Journal of Clinical Oncology 41 (15), 2789, 2023 | 41 | 2023 |
| Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer Y Fujita, S Yagishita, F Takeshita, Y Yamamoto, K Kuwano, T Ochiya Oncotarget 6 (5), 3335, 2015 | 35 | 2015 |
| A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small … H Mizugaki, N Yamamoto, H Nokihara, Y Fujiwara, H Horinouchi, ... Cancer chemotherapy and pharmacology 76, 1063-1072, 2015 | 30 | 2015 |
| Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer S Yagishita, Y Fujita, S Kitazono, R Ko, Y Nakadate, T Sawada, ... Molecular Cancer Therapeutics 14 (6), 1414-1423, 2015 | 29 | 2015 |
| Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab H Jo, T Yoshida, H Horinouchi, S Yagishita, Y Matsumoto, Y Shinno, ... Cancer Immunology, Immunotherapy, 1-12, 2022 | 26 | 2022 |
| Chaperone‐mediated autophagy receptor modulates tumor growth and chemoresistance in non–small cell lung cancer A Ichikawa, Y Fujita, Y Hosaka, T Kadota, A Ito, S Yagishita, N Watanabe, ... Cancer Science 111 (11), 4154-4165, 2020 | 24 | 2020 |
| Dasatinib Suppresses TGFβ-Mediated Epithelial–Mesenchymal Transition in Alveolar Epithelial Cells and Inhibits Pulmonary Fibrosis R Kanemaru, F Takahashi, M Kato, Y Mitsuishi, K Tajima, H Ihara, ... Lung 196, 531-541, 2018 | 23 | 2018 |
| Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions C Morita, T Yoshida, M Shirasawa, K Masuda, Y Matsumoto, Y Shinno, ... Scientific reports 11 (1), 18762, 2021 | 19 | 2021 |
| Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells T Sawada, M Watanabe, Y Fujimura, S Yagishita, T Shimoyama, Y Maeda, ... Cancer science 107 (3), 307-314, 2016 | 18 | 2016 |
| Impact of KRAS mutation on response and outcome of patients with stage III non‐squamous non‐small cell lung cancer S Yagishita, H Horinouchi, KS Sunami, S Kanda, Y Fujiwara, H Nokihara, ... Cancer Science 106 (10), 1402-1407, 2015 | 18 | 2015 |
| Visualization of intratumor pharmacokinetics of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2 heterogeneous model using phosphor-integrated dots imaging analysis M Suzuki, S Yagishita, K Sugihara, Y Ogitani, T Nishikawa, M Ohuchi, ... Clinical Cancer Research 27 (14), 3970-3979, 2021 | 17 | 2021 |
| Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging S Ryu, M Ohuchi, S Yagishita, T Shimoi, K Yonemori, K Tamura, ... Scientific Reports 10 (1), 15535, 2020 | 15 | 2020 |
